Treatment of progressive supranuclear palsy and corticobasal degeneration

Movement Disorders

Volumn 20, Issue SUPPL. 12, 2005, Pages

  Lang, Anthony E ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Corticobasal degeneration; Dopaminergic drugs; Dystonia; Myoclonus; Progressive supranuclear palsy; Tauopathy

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; AMANTADINE; AMITRIPTYLINE; ANIRACETAM; BACLOFEN; BOTULINUM TOXIN; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; DESIPRAMINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; EFAROXAN; FLUOXETINE; IDAZOXAN; LEVODOPA; LISURIDE; METHYSERGIDE; NALOXONE; PERGOLIDE; PHYSOSTIGMINE; PRAMIPEXOLE; PROPRANOLOL; SCOPOLAMINE; SELEGILINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THREO 3,4 DIHYDROXYPHENYLSERINE; UNINDEXED DRUG; ZOLPIDEM;

CLINICAL FEATURE; CLINICAL TRIAL; CORTICOBASAL DEGENERATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DRUG MECHANISM; DRUG RESPONSE; DYSKINESIA; DYSTONIA; ELECTROCONVULSIVE THERAPY; HUMAN; MOTOR DYSFUNCTION; MYOCLONUS; NERVE DEGENERATION; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW;

AMANTADINE; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; CORPUS STRIATUM; DOPAMINE AGENTS; DOPAMINE AGONISTS; DYSTONIA; GLOBUS PALLIDUS; HUMANS; INDANS; LEVODOPA; NERVE DEGENERATION; PIPERIDINES; SUBSTANTIA NIGRA; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 26444434929     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20545     Document Type: Review

References (46)

1. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
2. Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 2003;18(9):1018-1026.
3. Blin J, Baron JC, Dubois B, et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990;47:747-752.
4. Golbe LI. The epidemiology of PSP. J Neural Transm Suppl 1994;42:263-273.
5. Tolosa E, Valldeoriola F, Marti MJ. Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). J Neural Transm 1994;98(Suppl. 42): 15-31.
6. Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry 1995;58:167-173.
7. Verny M, Jellinger KA, Hauw JJ, Bancher C, Litvan I, Agid Y. Progressive supranuclear palsy: a clinicopathological study of 21 cases. Acta Neuropathol (Berl) 1996;91:427-431.
8. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996;47:1-9.
9. Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 2002;17:1255-1264.
10. Morris HR, Gibb G, Katzenschlager R, et al. Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain 2002;125:969-975.
11. Donaldson IM. The treatment of progressive supranuclear palsy with L-dopa. Aust N Z J Med 1973;3:413-416.
12. Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998;55:1099-1102.
13. Klawans HL, Jr., Ringel SP. Observations on the efficacy of L-dopa in progressive supranuclear palsy. Eur Neurol 1971;5:115-129.
14. Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 1983;13:273-278.
15. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993;16:338-346.
16. Weiner WJ, Minagar A, Shulman LM. Pramipexole in progressive supranuclear palsy. Neurology 1999;52:873-874.
17. Rafal RD, Grimm RJ. Progressive supranuclear palsy: functional analysis of the response to methysergide and anti parkinsonian agents. Neurology 1981;31:1507-1518.
18. Paulson GW, Lowery HW, Taylor GC. Progressive supranuclear palsy: pneumoencephalography, electronystagmography and treatment with methysergide. Eur Neurol 1981;20:13-16.
19. Duncombe AS, Lees AJ. Methysergide in progressive supranuclear palsy. Neurology 1985;35:936-937.
20. Rafal RD. Methysergide in progressive supranuclear palsy. Reply from the author. Neurology 1985;35:936-937.
21. Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991;41:986-991.
22. Rascol O, Sieradzan K, Peyro SP, et al. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov Disord 1998;13:673-676.
23. Yamamoto M, Fujii S, Hatanaka Y. Result of long-term administration of L-threo-3,4- dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy. Clin Neuropharmacol 1997;20:371-373.
24. Newman GC. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 1985;35:1189-1193.
25. Litvan I, Blesa R, Clark K, et al. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 1994;36:55-61.
26. Foster NL, Aldrich MS, Bluemlein L, White RF, Berent S. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 1989; 39(Pt 1):257-261.
27. Litvan I, Gomez C, Atack JR, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 1989;26:404-407.
28. Kertzman C, Robinson DL, Litvan I. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 1990;47:1346-1350.
29. Fabbrini G, Barbanti P, Bonifati V, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand 2001; 103:123-125.
30. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001;57:467-473.
31. Nagasaka T, Togashi S, Amino A, Nitta K, Shindo K, Shiozawa Z. Aniracetam for treatment of patients with progressive supranuclear palsy. Eur Neurol 1997;37:195-198.
32. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999;341:543-544.
33. Mayr BJ, Bonelli RM, Niederwieser G, Koltringer P, Reisecker F. Zolpidem in progressive supranuclear palsy. Eur J Neurol 2002;9: 184-185.
34. Hauser RA, Trehan R. Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Mov Disord 1994;9: 467-469.
35. Barclay CL, Duff J, Sandor P, Lang AE. Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy. Neurology 1996;46:1284-1286.
36. Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 2001; 16:907-913.
37. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995;45:712-717.
38. Aramideh M, De Visser BWO, Brans JWM, Koelman JHTM, Speelman JD. Pretarsal application of botulinum toxin for treatment of blepharospasm. J Neurol Neurosurg Psychiatry 1995;59: 309-311.
39. Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry 1996;60:704.
40. Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-247.
41. Mancini F, Zangaglia R, Cristina S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003;18:685-688.
42. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003;54:S15-S19.
43. Lang AE, Riley DE, Bergeron C. Cortical-basal ganglionic degeneration. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: WB Saunders; 1994. p 877-894.
44. Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998;55:957-961.
45. Frucht S, Fahn S, Chin S, Dhawan V, Eidelberg D. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration. Mov Disord 2000;15:340-343.
46. Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002; 17:1318-1320.